Trends in prescribing practices for management of haemophilia: 1999-2021.

Randall G Curtis Jonathan C Roberts Nicole Crook Marquita Decker-Palmer Rahul Khairnar Judith R Baker Megan M Ullman Marion A Koerper Joanne Wu Michael B Nichol

Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)

These data indicate changing trends in prescribing practices among US haemophilia specialists during the past 22 years. Preference for high doses of factor (>40 units/kg) has increased during this period. Emicizumab prophylaxis has been prescribed for patients with and without HA inhibitors. Clinicians expect gene therapy to have value for some haemophilia patients.

Keyphrases

primary care
gene therapy
end stage renal disease
healthcare
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
palliative care
electronic health record
big data
deep learning